European and Italian regulation on orphan medicinal products
DOI:
https://doi.org/10.7175/fe.v14i2.633Keywords:
Orphan drugs, Rare diseases, Pharmaceutical legislationAbstract
The paper presents an overview of the European and Italian Regulation on Orphan Medicinal Products (OMPs), along with some data on the OMPs licensed in the EU from 2000 to 2012. The EU legislation encourages pharmaceutical companies to develop drugs for rare diseases, so-called “orphan drugs”. The European Medicine Agency recognizes orphan drug status mainly on the basis of the prevalence of the disease (≤ 5/10,000), and potential benefit. Orphan status implies incentives for pharmaceutical companies. From 2000 up to 2012 890 candidate orphan drug designations received a positive opinion and the marketing authorization was granted to 72 OMPs corresponding to 80 different indications. Currently, 59 OMPs are available to Italian patients either because licensed to the market by the AIFA or included in the list of the L. 648/96. Despite of an encouraging regulation nearly all the currently estimated rare diseases still await treatments.
References
Orphanet. The portal for rare diseases and orphan drugs. Disponibile su: http://www.orpha.net/consor/cgi-bin/index.php?lng0EN&lng=IT (ultimo accesso: marzo 2013)
Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Off J Eur Communities 2000; L18: 1-5
EMA. Rare disease (orphan) designations. Available at: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan_search.jsp&mid=WC0b01ac058001d12b (ultimo accesso:marzo 2013)
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Official Journal 2011; L 311: 67. Disponibile su:http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20070126:en:PDF (ultimo accesso: marzo 2013)
Decreto Ministero della Sanità - 18 maggio 2001, n. 279. Regolamento di istituzione della rete nazionale delle malattie rare e di esenzione dalla partecipazione al costo delle relative prestazioni sanitarie ai sensi dell’articolo 5, comma 1, lettera b) del decreto legislativo 29 aprile 1998, n. 124. G.U. 12 luglio 2001, n. 160
ISS. Registro Nazionale Malattie Rare. Disponibile su: http://www.iss.it/cnmr/regi/cont.php?id=860&lang=1&tipo=14
Taruscio D. Il Registro Nazionale e i Registri Regionali/interregionali delle malattie rare. Rapporto anno 2011. ISS 2011; Rapporti ISTISAN 11/20. Disponibile su: http://www.iss.it/binary/cnmr/cont/ISTISAN_RNMR_2011.pdf
Legge 23/12/96 n. 648 di conversione del decreto-legge 21/10/96 n. 536 (G.U. n. 300 del 23 dicembre 1996)
Elenco farmaci erogabili a totale carico del SSN ai sensi della legge 648/96 e relative indicazioni terapeutiche. Disponibile su http://www.agenziafarmaco.gov.it (ultimo accesso: marzo 2013)
ISS. Registro Nazionale Farmaci Orfani. Disponibile su: http://www.iss.it/orfa/regi/cont.php?id=71&lang=1&tipo=4. (ultimo accesso: marzo 2013)
EMA. Thelin (sitaxentan) – Withdrawal of the marketing authorisation in the European Union. EMA/149536/2011. Disponibile su: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2011/03/WC500102595.pdf
Joppi R, Bertele V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 2013; 69: 1009-24; http://dx.doi.org/10.1007/s00228-012-1423-2
Osservatorio Nazionale sull’impiego dei medicinali. L’Uso dei Farmaci in Italia. Rapporto nazionale anno 2011.
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
